Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Cancer and Oncology›Sturge-Weber Syndrome
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Sturge-Weber Syndrome

Cancer and Oncology · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 4 min read

A non-inherited congenital condition with vascular and neurological abnormalities.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (823 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A non-inherited congenital condition with vascular and neurological abnormalities. It is characterized by facial vascular nevi (port-wine stain), and capillary angiomatosis of intracranial membranes (meninges; choroid). Neurological features include epilepsy; cognitive deficits; glaucoma; and visual defects.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Sturge Weber Syndrome; Syndrome, Sturge-Weber; Phakomatosis, Sturge-Weber; Phakomatosis, Sturge Weber; Sturge-Weber Phakomatosis; Sturge Disease; Sturge Syndrome; Syndrome, Sturge.

Where it fits in the MeSH classification

Broader topics
Hemangioma; Neurocutaneous Syndromes; Angiomatosis

Related concepts

  • Port-Wine Stain
  • Meninges
  • Choroid
  • Epilepsy
  • Glaucoma

Research landscape

PubMed indexes 1,485 records tagged with the MeSH heading “Sturge-Weber Syndrome” (counts retrieved 2026-10-29). 226 of them (15.2%) were published from 2020 onward, and the busiest period so far is through 1999 with 588 records.

Reviews account for 187 records (12.6%) and meta-analyses for 2. Randomized controlled trials number 2 (0.1%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 588 records; 2000-2009: 295 records; 2010-2019: 376 records; 2020 onward: 226 records588through 19992952000-20093762010-20192262020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 1999588
2000-2009295
2010-2019376
2020 onward226
Share of records by publication typeReviews: 12.6 percent; Meta-analyses: 0.1 percent; Randomized controlled trials: 0.1 percentReviews12.6% (187)Meta-analyses0.1% (2)Randomized controlled trials0.1% (2)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 1,485 PubMed records
TypeRecordsShare
Reviews18712.6%
Meta-analyses20.1%
Randomized controlled trials20.1%

Method: PubMed query "Sturge-Weber Syndrome"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in cancer and oncology

Cancer research spans very different kinds of evidence. Laboratory studies in cell lines and animal models reveal mechanisms but often do not translate to patients. Early-phase trials mainly test safety and dosing, while phase 3 randomized trials and their meta-analyses are the usual basis for treatment conclusions. Outcomes also differ in meaning: tumour shrinkage, progression-free survival and overall survival are not interchangeable, and screening studies can be distorted by lead-time and overdiagnosis. When reading a result, check the cancer type and stage studied, the comparison treatment, and which outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
The Pathogenesis of Port Wine Stain and Sturge Weber Syndrome: Complex Interactions between Genetic Alterations and Aberrant MAPK and PI3K Activation
Nguyen V, Hochman M, Mihm MC, Nelson JS, Tan W
2019Review article
Design not recorded in structured metadata
83cc by
PMID 31067686 · DOI · PMC6539103
Ophthalmic Alterations in the Sturge-Weber Syndrome, Klippel-Trenaunay Syndrome, and the Phakomatosis Pigmentovascularis: An Independent Group of Conditions?
Abdolrahimzadeh S, Scavella V, Felli L, Cruciani F, Contestabile MT, Recupero SM
2015Review article
Design not recorded in structured metadata
50cc by
PMID 26451379 · DOI · PMC4588354
A novel somatic mutation in GNB2 provides new insights to the pathogenesis of Sturge-Weber syndrome
Fjær R, Marciniak K, Sundnes O, Hjorthaug H, Sheng Y, Hammarström C, et al.
2021Research article
Design not recorded in structured metadata
37cc by
PMID 34124757 · DOI · PMC8522634
In Vitro Models of Sturge-Weber Syndrome: Strengths, Limitations, and Future Goals
Manney AB, Nemeth CL, Comi AM
2026Review article
Design not recorded in structured metadata
0cc by
PMID 42123678 · DOI · PMC13163291

The Pathogenesis of Port Wine Stain and Sturge Weber Syndrome: Complex Interactions between Genetic Alterations and Aberrant MAPK and PI3K Activation [1]

Review article Nguyen V, Hochman M, Mihm MC, Nelson JS, Tan W · · 2019 · cited 83 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Port wine stain (PWS) is a congenital vascular malformation involving human skin.
Closing excerpt
We also address many crucial questions yet to be answered in the future research investigations.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (231 words)

Port wine stain (PWS) is a congenital vascular malformation involving human skin. Approximately 15-20% of children a facial PWS involving the ophthalmic (V1) trigeminal dermatome are at risk for Sturge Weber syndrome (SWS), a neurocutaneous disorder with vascular malformations in the cerebral cortex on the same side of the facial PWS lesions. Recently, evidence has surfaced that advanced our understanding of the pathogenesis of PWS/SWS, including discoveries of somatic genetic mutations (GNAQ, PI3K), MAPK and PI3K aberrant activations, and molecular phenotypes of PWS endothelial cells. In this review, we summarize current knowledge on the etiology and pathology of PWS/SWS based on evidence that the activation of MAPK and/or PI3K contributes to the malformations, as well as potential futuristic treatment approaches targeting these aberrantly dysregulated signaling pathways. Current data support that: (1) PWS is a multifactorial malformation involving the entire physiological structure of human skin; (2) PWS should be pathoanatomically re-defined as "a malformation resulting from differentiation-impaired endothelial cells with a progressive dilatation of immature venule-like vasculatures"; (3) dysregulation of vascular MAPK and/or PI3K signaling during human embryonic development plays a part in the pathogenesis and progression of PWS/SWS; and (4) sporadic low frequency somatic mutations, such as GNAQ, PI3K, work as team players but not as a lone wolf, contributing to the development of vascular phenotypes. We also address many crucial questions yet to be answered in the future research investigations.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31067686 · DOI · PMC6539103

Ophthalmic Alterations in the Sturge-Weber Syndrome, Klippel-Trenaunay Syndrome, and the Phakomatosis Pigmentovascularis: An Independent Group of Conditions? [2]

Review article Abdolrahimzadeh S, Scavella V, Felli L, Cruciani F, Contestabile MT, Recupero SM · · 2015 · cited 50 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The phakomatoses have been traditionally defined as a group of hereditary diseases with variable expressivity characterized by multisystem tumors with possible malignant transformation.
Closing excerpt
Although the multiple pathophysiological mechanisms still require clarification, similarities in ophthalmic manifestations make it reasonable to classify these diseases in an independent group.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (183 words)

The phakomatoses have been traditionally defined as a group of hereditary diseases with variable expressivity characterized by multisystem tumors with possible malignant transformation. The Sturge-Weber syndrome, Klippel-Trenaunay syndrome, and the phakomatosis pigmentovascularis have the facial port-wine stain in common. Numerous pathophysiogenetic mechanisms have been suggested such as venous dysplasia of the emissary veins in the intracranial circulation, neural crest alterations leading to alterations of autonomic perivascular nerves, mutation of the GNAO gene in the Sturge-Weber syndrome, PIK3CA mutation in malformative/overgrowth syndromes such as the Klippel-Trenaunay syndrome, and the twin-spotting phenomenon in phakomatosis pigmentovascularis. Other features linked to the port-wine stain and typical to all of the three conditions are glaucoma and choroidal alterations. Glaucoma can be due to malformations of the anterior chamber or high episcleral venous pressure and in phakomatosis pigmentovascularis it can also be associated with angle hyperpigmentation. The choroid can be thickened in all diseases. Furthermore, choroidal melanocytosis in the phakomatosis pigmentovascularis can lead to malignant transformation. Although the multiple pathophysiological mechanisms still require clarification, similarities in ophthalmic manifestations make it reasonable to classify these diseases in an independent group.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 26451379 · DOI · PMC4588354

A novel somatic mutation in GNB2 provides new insights to the pathogenesis of Sturge-Weber syndrome [3]

Research article Fjær R, Marciniak K, Sundnes O, Hjorthaug H, Sheng Y, Hammarström C, et al. · · 2021 · cited 37 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Sturge-Weber syndrome (SWS) is a neurocutaneous disorder characterized by vascular malformations affecting skin, eyes and leptomeninges of the brain, which can lead to glaucoma, seizures and intellectual disability.
Closing excerpt
The discovery of the GNB2 mutation sheds novel light on the pathogenesis of SWS and suggests that future research on targets of treatment should be directed towards the YAP, rather than the MAPK, signalling pathway.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (255 words)

Sturge-Weber syndrome (SWS) is a neurocutaneous disorder characterized by vascular malformations affecting skin, eyes and leptomeninges of the brain, which can lead to glaucoma, seizures and intellectual disability. The discovery of a disease-causing somatic missense mutation in the GNAQ gene, encoding an alpha chain of heterotrimeric G-proteins, has initiated efforts to understand how G-proteins contribute to SWS pathogenesis. The mutation is predominantly detected in endothelial cells and is currently believed to affect downstream MAPK signalling. In this study of six Norwegian patients with classical SWS, we aimed to identify somatic mutations through deep sequencing of DNA from skin biopsies. Surprisingly, one patient was negative for the GNAQ mutation, but instead harbored a somatic mutation in GNB2 (NM_005273.3:c.232A>G, p.Lys78Glu), which encodes a beta chain of the same G-protein complex. The positions of the mutant amino acids in the G-protein are essential for complex reassembly. Therefore, failure of reassembly and continuous signalling is a likely consequence of both mutations. Ectopic expression of mutant proteins in endothelial cells revealed that expression of either mutant reduced cellular proliferation, yet regulated MAPK signalling differently, suggesting that dysregulated MAPK signalling cannot fully explain the SWS phenotype. Instead, both mutants reduced synthesis of Yes-associated protein (YAP), a transcriptional co-activator of the Hippo signalling pathway, suggesting a key role for this pathway in the vascular pathogenesis of SWS. The discovery of the GNB2 mutation sheds novel light on the pathogenesis of SWS and suggests that future research on targets of treatment should be directed towards the YAP, rather than the MAPK, signalling pathway.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34124757 · DOI · PMC8522634

In Vitro Models of Sturge-Weber Syndrome: Strengths, Limitations, and Future Goals [4]

Review article Manney AB, Nemeth CL, Comi AM · · 2026

Abstract reading summary — source excerpts
Opening excerpt
Sturge-Weber Syndrome (SWS) is a rare congenital disorder presenting with a vascular malformation in the upper face and brain, causing impaired blood-brain barrier function and perfusion, increased calcium signaling, inflammation, and seizures.
Closing excerpt
Ongoing in vitro work seeks to overcome these limitations, shape our understanding of SWS, and lead to translational advances in treatment and prevention by studying the affected molecular pathways and identifying future targets for therapy.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (154 words)

Sturge-Weber Syndrome (SWS) is a rare congenital disorder presenting with a vascular malformation in the upper face and brain, causing impaired blood-brain barrier function and perfusion, increased calcium signaling, inflammation, and seizures. All these neuropathologic processes result in injury to the brain. The somatic GNAQ R183Q variant, which accounts for the majority of SWS cases, increases signaling through MAPK, PI3K, mTOR, and inflammatory pathways, primarily in endothelial cells. The discovery of this variant enabled the creation of transgenic and genetic animal and cell culture models. Generating in vitro models has been challenging due to the mosaic nature of SWS, and attempts to separate unaffected from mutant cells in primary culture have failed, limiting the utility of in vitro work. Ongoing in vitro work seeks to overcome these limitations, shape our understanding of SWS, and lead to translational advances in treatment and prevention by studying the affected molecular pathways and identifying future targets for therapy.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42123678 · DOI · PMC13163291

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Sturge-Weber syndrome: a review [5]
    Thomas-Sohl KA, Vaslow DF, Maria BL · Pediatr Neurol · 2004 · cited 194 times (Europe PMC)
  • Research article Pathophysiology of Sturge-Weber syndrome [6]
    Comi AM · J Child Neurol · 2003 · cited 128 times (Europe PMC)
  • Research article Neurocutaneous syndromes [7]
    Roach ES · Pediatr Clin North Am · 1992 · cited 122 times (Europe PMC)
  • Research article Presentation, diagnosis, pathophysiology, and treatment of the neurological features of Sturge-Weber syndrome [8]
    Comi AM · Neurologist · 2011 · cited 105 times (Europe PMC)
  • Research article Update on Sturge-Weber syndrome: diagnosis, treatment, quantitative measures, and controversies [9]
    Comi AM · Lymphat Res Biol · 2007 · cited 96 times (Europe PMC)
  • Research article Sturge-Weber syndrome: from the past to the present [10]
    Sudarsanam A, Ardern-Holmes SL · Eur J Paediatr Neurol · 2014 · cited 95 times (Europe PMC)

References

  1. Nguyen V, Hochman M, Mihm MC, Nelson JS, Tan W. The Pathogenesis of Port Wine Stain and Sturge Weber Syndrome: Complex Interactions between Genetic Alterations and Aberrant MAPK and PI3K Activation. . 2019. PMID 31067686 · DOI · PMC6539103
  2. Abdolrahimzadeh S, Scavella V, Felli L, Cruciani F, Contestabile MT, Recupero SM. Ophthalmic Alterations in the Sturge-Weber Syndrome, Klippel-Trenaunay Syndrome, and the Phakomatosis Pigmentovascularis: An Independent Group of Conditions?. . 2015. PMID 26451379 · DOI · PMC4588354
  3. Fjær R, Marciniak K, Sundnes O, Hjorthaug H, Sheng Y, Hammarström C, et al.. A novel somatic mutation in GNB2 provides new insights to the pathogenesis of Sturge-Weber syndrome. . 2021. PMID 34124757 · DOI · PMC8522634
  4. Manney AB, Nemeth CL, Comi AM. In Vitro Models of Sturge-Weber Syndrome: Strengths, Limitations, and Future Goals. . 2026. PMID 42123678 · DOI · PMC13163291
  5. Thomas-Sohl KA, Vaslow DF, Maria BL. Sturge-Weber syndrome: a review. Pediatr Neurol. 2004. PMID 15165630 · DOI
  6. Comi AM. Pathophysiology of Sturge-Weber syndrome. J Child Neurol. 2003. PMID 13677575 · DOI
  7. Roach ES. Neurocutaneous syndromes. Pediatr Clin North Am. 1992. PMID 1635798 · DOI
  8. Comi AM. Presentation, diagnosis, pathophysiology, and treatment of the neurological features of Sturge-Weber syndrome. Neurologist. 2011. PMID 21712663 · DOI · PMC4487915
  9. Comi AM. Update on Sturge-Weber syndrome: diagnosis, treatment, quantitative measures, and controversies. Lymphat Res Biol. 2007. PMID 18370916 · DOI
  10. Sudarsanam A, Ardern-Holmes SL. Sturge-Weber syndrome: from the past to the present. Eur J Paediatr Neurol. 2014. PMID 24275166 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • MeningiomaCancer and Oncology
  • AngiomatosisCardiovascular Medicine
  • von Hippel-Lindau DiseaseRare and Inherited Diseases
  • WineAnatomy and Physiology
  • Limbic EncephalitisCancer and Oncology
  • GliomaCancer and Oncology

All 107 articles in Cancer and Oncology →

At a glance

1,485
PubMed records on this heading
15%
published since 2020
187
review articles
2
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • MeningiomaCancer and Oncology
  • AngiomatosisCardiovascular Medicine
  • von Hippel-Lindau DiseaseRare and Inherited Diseases
  • WineAnatomy and Physiology
  • Limbic EncephalitisCancer and Oncology

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support